Given that several mTOR inhibitors and S6K1 inhibitors have been tested as adjuvants of chemotherapy [46,47], further study of the potential application of evodiamine and TRAIL combination in bladder cancer therapy is warranted. This evidence concerns the gene RPS6KB1 and urinary bladder carcinoma.